ENTYVIO® (Vedolizumab) is an anti-inflammatory drug used to treat Inflammatory Bowel Diseases.
ENTYVIO® is manufactured by Takeda.
Administration and Dosage:
Administration of ENTYVIO® follows an induction regimen of 3 intravenous infusions at 0, 2, and 6 weeks followed by a maintenance infusion, once every 8 weeks.
Common Side Effects:
The more common side effects of ENTYVIO® include infusion-related and serious allergic reactions, infections, Progressive Multifocal Leukoencephalopathy (PML), and liver problems.
Ready to Schedule an Appointment?
Please CLICK HERE to get started.
ENTYVIO® is indicated to treat:
- Crohn’s Disease
- Ulcerative Colitis